title: Methyl selenocysteine: single-dose pharmacokinetics in men.
abstract: The recently published report of the SELECT evaluation of selenium and vitamin E provided strong evidence that selenium 200 μg per day in the form of selenomethionine does not protect selenium-replete men against prostate or any other cancer. This seems to refute the result of the much smaller Nutritional Prevention of Cancer (NPC) trial of selenium. Because SELECT did not test the NPC agent, it is possible that the difference between the two trials stems partly from the use of different agents: selenomethionine in SELECT, and selenized yeast in the NPC trial. One of the organic selenium forms suspected of having strong chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine. This study characterizes the single-dose pharmacokinetics of methyl selenocysteine.
authors.affiliation: Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA. james.marshall@roswellpark.org
authors.forename: James R
authors.initials: JR
authors.lastname: Marshall
authors.forename: Clement
authors.initials: C
authors.lastname: Ip
authors.forename: Karen
authors.initials: K
authors.lastname: Romano
authors.forename: Gerald
authors.initials: G
authors.lastname: Fetterly
authors.forename: Marwan
authors.initials: M
authors.lastname: Fakih
authors.forename: Borko
authors.initials: B
authors.lastname: Jovanovic
authors.forename: Marjorie
authors.initials: M
authors.lastname: Perloff
authors.forename: James
authors.initials: J
authors.lastname: Crowell
authors.forename: Warren
authors.initials: W
authors.lastname: Davis
authors.forename: Renee
authors.initials: R
authors.lastname: French-Christy
authors.forename: Alexander
authors.initials: A
authors.lastname: Dew
authors.forename: Margerie
authors.initials: M
authors.lastname: Coomes
authors.forename: Raymond
authors.initials: R
authors.lastname: Bergan
mesh_terms: D000328:Adult; D015331:Cohort Studies; D003545:Cysteine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D016566:Organoselenium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017279:Selenocysteine / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D016566:Organoselenium Compounds; D017279:Selenocysteine; D003545:Cysteine; C002979:selenomethylselenocysteine